These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 14509130

  • 1. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects.
    Nesher R, Ticho U.
    Isr Med Assoc J; 2003 Apr; 5(4):260-3. PubMed ID: 14509130
    [Abstract] [Full Text] [Related]

  • 2. Topical carbonic anhydrase inhibitors and visual function in glaucoma and ocular hypertension.
    Gugleta K.
    Curr Med Res Opin; 2010 Jun; 26(6):1255-67. PubMed ID: 20350146
    [Abstract] [Full Text] [Related]

  • 3. A multicenter study comparing dorzolamide and pilocarpine as adjunctive therapy to timolol: patient preference and impact on daily life.
    Strohmaier K, Snyder E, Adamsons I.
    J Am Optom Assoc; 1998 Jul; 69(7):441-51. PubMed ID: 9697378
    [Abstract] [Full Text] [Related]

  • 4. [Treatment of glaucoma with carbonic anhydrase inhibitors in eyewash: medium term retrospective experience with dorzolamide].
    Detry-Morel M, De Hoste F.
    Bull Soc Belge Ophtalmol; 1997 Jul; 267():157-66. PubMed ID: 9745826
    [Abstract] [Full Text] [Related]

  • 5. Results of the European Glaucoma Prevention Study.
    Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I, European Glaucoma Prevention Study (EGPS) Group.
    Ophthalmology; 2005 Mar; 112(3):366-75. PubMed ID: 15745761
    [Abstract] [Full Text] [Related]

  • 6. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Manni G, Denis P, Chew P, Sharpe ED, Orengo-Nania S, Coote MA, Laganovska G, Volksone L, Zeyen T, Filatori I, James J, Aung T.
    J Glaucoma; 2009 Mar; 18(4):293-300. PubMed ID: 19365194
    [Abstract] [Full Text] [Related]

  • 7. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
    Maruyama K, Shirato S.
    J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
    Ozturk F, Ermis SS, Inan UU.
    Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
    Katz LJ, Simmons ST, Craven ER.
    Curr Med Res Opin; 2007 Dec; 23(12):2971-83. PubMed ID: 17949534
    [Abstract] [Full Text] [Related]

  • 10. Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices.
    Gugleta K, Orgül S, Flammer J.
    Curr Med Res Opin; 2003 Dec; 19(4):330-5. PubMed ID: 12841926
    [Abstract] [Full Text] [Related]

  • 11. Dorzolamide, a 40-year wait. From an oral to a topical carbonic anhydrase inhibitor for the treatment of glaucoma.
    Ponticello GS, Sugrue MF, Plazonnet B, Durand-Cavagna G.
    Pharm Biotechnol; 1998 Dec; 11():555-74. PubMed ID: 9760696
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension.
    Lesk MR, Koulis T, Sampalis F, Sampalis JS, Bastien NR.
    Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402
    [Abstract] [Full Text] [Related]

  • 13. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
    Balfour JA, Wilde MI.
    Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858
    [Abstract] [Full Text] [Related]

  • 14. A trial of dorzolamide for glaucoma.
    Gillies WE, Brooks AM.
    Ophthalmic Surg Lasers; 1998 Sep; 29(9):728-32. PubMed ID: 9760608
    [Abstract] [Full Text] [Related]

  • 15. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
    Bournias TE, Lai J.
    Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
    [Abstract] [Full Text] [Related]

  • 16. Comparison of twice-daily and three-times-daily dosing of dorzolamide in ocular hypertension and primary open-angle glaucoma patients treated with latanoprost.
    Lupinacci AP, Netland PA, Fung KH, Evans D, Zhao Y.
    Adv Ther; 2008 Mar; 25(3):231-9. PubMed ID: 18369537
    [Abstract] [Full Text] [Related]

  • 17. Comparison of latanoprost and dorzolamide in the treatment of patients with open angle glaucoma.
    Niazi MK, Raja N.
    J Ayub Med Coll Abbottabad; 2004 Mar; 16(1):50-3. PubMed ID: 15125183
    [Abstract] [Full Text] [Related]

  • 18. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
    Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA.
    Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
    [Abstract] [Full Text] [Related]

  • 19. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation.
    Rosenberg LF, Krupin T, Tang LQ, Hong PH, Ruderman JM.
    Ophthalmology; 1998 Jan; 105(1):88-92; discussion 92-3. PubMed ID: 9442783
    [Abstract] [Full Text] [Related]

  • 20. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor.
    Wilkerson M, Cyrlin M, Lippa EA, Esposito D, Deasy D, Panebianco D, Fazio R, Yablonski M, Shields MB.
    Arch Ophthalmol; 1993 Oct; 111(10):1343-50. PubMed ID: 8216014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.